Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison

INTRODUCTION: The Phase III FUTURE I and II trials demonstrated the clinical efficacy of secukinumab in active psoriatic arthritis (PsA). In the absence of head-to-head trials, this study compared the clinical efficacy and cost effectiveness of adalimumab 40 mg versus secukinumab 150 and 300 mg for...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Betts, Keith A., Mittal, Manish, Song, Jinlin, Skup, Martha, Joshi, Avani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696282/
https://www.ncbi.nlm.nih.gov/pubmed/28762213
http://dx.doi.org/10.1007/s40744-017-0070-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696282/
https://www.ncbi.nlm.nih.gov/pubmed/28762213
http://dx.doi.org/10.1007/s40744-017-0070-6

Ejemplares similares